STRO-001 is under clinical development by Sutro Biopharma and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase I drugs for Refractory Multiple Myeloma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STRO-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

STRO-001 overview

STRO-001 is under development for the treatment of relapsed and refractory advanced B-Cell malignancies such as multiple myeloma, diffuse large B-cell lymphoma, follicular lymphoma, Burkitt lymphoma, acute myeloid leukemia (AML), marginal zone b-cell lymphoma, hematologic malignancies and mantle cell lymphoma. It is administered through intravenous route. The therapeutic candidate is a monoclonal antibody conjugate targeting cells expressing CD74. It is based on Xpress CF technology using non-natural amino acids.

Sutro Biopharma overview

Sutro Biopharma is a clinical-stage oncology company. It develops next-generation cancer therapeutics which include antibody-drug conjugates (ADCs), bispecific antibodies, cytokine-based immuno-oncology therapies and vaccines through the XpressCF and XpressCF+ platforms. The company’s pipeline products include STRO-001 to treat B-cell malignancies; STRO-002, luvelta treats ovarian cancer, endometrial cancer, adenocarcinoma, non-small cell lung cancer, GLlS2 pediatric acute myeloid leukemia; STRO-003 treats solid tumors, hematological cancers, STRO-004 treat solid tumors, VAX-24, MK-1484 treats invasive pneumococcal disease and metastatic solid tumors. It works in collaboration with Merck & Co., Inc and Astellas Pharma Inc., among others. Sutro Biopharma is headquartered in South San Francisco, California, the US.

For a complete picture of STRO-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.